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The establishment of distant metastases depends on the capacity
of small numbers of cancer cells to regenerate a tumor after
entering a target tissue. The mechanisms that confer this capacity
remain to be defined. Here we identify a role for the transcriptional
inhibitors of differentiation Id1 and Id3 as selective mediators of
lung metastatic colonization in the triple negative [TN, i.e., lacking
expression of estrogen receptor and progesterone receptor, and
lacking Her2 (human epidermal growth factor receptor 2) ampli-
fication] subgroup of human breast cancer. Although broad ex-
pression of Id1 has recently been documented in tumors of the rare
metaplastic subtype, here we report that rare Id1-expressing cells
are also present in the more common TN subset of human breast
tumors but not in other subtypes. We also provide evidence that
Id1 expression is enriched in clinically obtained hormone receptor
negative lung metastases. Functional studies demonstrate that Id1
and its closely related family member Id3 are required for tumor
initiating functions, both in the context of primary tumor forma-
tion and during metastatic colonization of the lung microenviron-
ment. In vivo characterization of lung metastatic progression
reveals that Id1 and Id3 facilitate sustained proliferation during the
early stages of metastatic colonization, subsequent to extravasa-
tion into the lung parenchyma. These results shed light on the
proliferative mechanisms that initiate metastatic colonization, and
they implicate Id1 and Id3 as mediators of this malignant function
in the TN subgroup of breast cancers.
proliferation  stem cells  triple negative
Cancer metastasis involves multiple steps through whichtumor cells ultimately colonize and overtake distant organs
(1, 2). After circulating tumors cells exit the bloodstream by
passing through the vascular wall into tissue parenchyma, they
require a capacity to reinitiate tumor growth to establish a
metastasic colony. Tumor cells that extravasate individually or in
small clusters may develop into full metastatic colonies only if
they have such tumor-initiating capacity. The tumor-initiating
capacity that is required for the establishment of metastatic
colonies is akin to the phenotypic state that is referred to as
‘‘cancer stem cell’’ (3). In a strict interpretation, this term may
designate stem cells that have become oncogenically trans-
formed and whose progeny build up a tumor, as it occurs in
certain leukemias (4) and in intestinal carcinomas (5). In a
broader sense, however, this concept also encompasses the case
of tumor cells that have co-opted certain gene functions con-
ferring upon these cells the capacity of tumor reinitiation after
metastatic seeding of distant organs. This reinitiation capacity is
regardless of whether such genes participate in the normal
self-renewal process of authentic stem cells. Therefore, the
identification of genes that confer this function is important for
understanding the molecular basis for cancer metastasis.
Analysis of gene expression patterns in human tumors of
different metastatic outcome has revealed gene sets, or ‘‘signa-
tures,’’ whose expression in a tumor is associated with a high risk
of relapse (6, 7). We recently used in vivo metastasis assays to
functionally filter genome-wide expression patterns of human
breast cancer cells. These studies resulted in the identification of
a set of candidate metastasis genes whose expression in primary
breast tumors is associated with a high risk of metastasis to the
lungs (8). This set of genes, the Lung Metastasis Signature
(LMS), includes 18 genes that support mammary tumor growth
as well as pulmonary metastasis by human breast cancer cells in
mice, and their expression in estrogen-receptor-negative (ER)
tumors indicates a high risk of pulmonary relapse in breast
cancer patients (8, 9). A majority of LMS genes encode cell
surface and secreted products that affect the interaction of the
tumor cells with the microenvironment. Some of these genes
collectively support tumor angiogenesis, entry of mammary
tumor cells into the circulation, and tumor cell exit from lung
capillaries into the pulmonary parenchyma (10). A notable
exception is the inhibitor of cell differentiation ID1, which is the
only transcriptional regulator present in the LMS.
The ID gene family (ID1 through ID4) are expressed in
progenitor cells in embryos and in certain adult tissues, and
control cell differentiation by antagonizing the DNA binding
activity of basic helix–loop–helix transcription factors (11, 12).
ID1 and ID3 function is required for the mobilization of endo-
thelial precursor cells from the bone marrow during pathological
tumor angiogenesis, and the expression of these genes remains
high in tumor neovasculature (12, 13). Broad ID expression has
been documented in metaplastic tumors of poor clinical out-
come (14). ID expression in more common cancer subtypes has
been a matter of debate, owing to disparate observations de-
pending on the cell line or tumor model used or the nature of the
antibodies against the gene products (11, 14, 15). The identifi-
cation of ID1 as a LMS gene focused our attention on the
hypothesis that ID gene expression confers tumor-initiating
capacity to rare breast cancer cells within the more common
types of breast tumors with high lung metastatic potential.
Results
Id1 Expression in Specific Breast Tumor Subtypes and Lung Metasta-
ses. Immunohistochemical studies using tissue microarrays
(TMA) recently revealed a substantial incidence (25% of
cases) of Id1 protein expression in the rare metaplastic breast
cancer subtype. The incidence of Id1 expression was lower
(2–3% of cases) in the more common subtype triple negative
[TN, i.e., lacking expression of estrogen receptor and proges-
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terone receptor, and lacking Her2 (human epidermal growth
factor receptor 2) amplification] (14). However, because of the
focal pattern of Id1 expression that is frequently observed, it
remained possible that evaluation of tumor samples by TMA
might underestimate the proportion of Id1 breast cancers. For
this reason, we conducted Id1 immunohistochemistry with a
mono-specific rabbit monoclonal antibody on whole tumor block
sections from 133 patients with breast cancer of various subtypes.
Among primary breast tumors that were not triple negative, only
1 of 105 exhibited Id1 expression within the tumor cell com-
partment (1%; Fig. 1 A and B). In contrast, 10 of 28 (36%) triple
negative [ER, progesterone-receptor-negative (PR), and
Her2] breast cancers contained cancer cells that were Id1
(Fig. 1 A and B). This proportion was even higher (6 of 7, 86%)
when examining the subset of triple negative tumors that exhib-
ited a metaplastic morphology (data not shown). Within these
Id1 samples, the frequency of Id1-expressing cancer cells was
consistently higher in metaplastic TN tumors (range 10–95%)
than it was in nonmetaplastic TN tumors (range 1–5%). As an
internal positive control, endothelial cells in all tumor subtypes
expressed abundant quantities of nuclear Id1 (Fig. 1A). These
findings are consistent with previous results (14) but likely
reflect a more accurate quantitation of rare Id1 positivity in
human breast cancer subtypes than the frequencies that were
previously attained by using TMA studies.
If Id1 augments the lung metastatic potential of breast tumor
cells, onewould predict that a greater proportion of lungmetastases
should contain Id1 cancer cells. To address this issue, we mea-
sured Id1 protein expression in 39 lung metastasis lesions surgically
extracted frombreast cancer patients. Ten of 39 (26%) of these lung
metastasis lesions showed Id1 staining (Fig. 1D). In 11 cases for
which primary and metastasis tissue were obtained from the same
patient, 3 out of 11 metastases were Id1, and indeed rare, focal
Id1 cells were observed in all 3 matched primaries. Hormone
receptor status was available for 32 of the 39 lung metastasis
samples. Intriguingly, 10 of 22 (45%) hormone-receptor-negative
(ER and PR) lung metastases were Id1, whereas 0 of 16
hormone-receptor-positive (ER and/or PR) lung metastases
expressed Id1 (Fig. 1D). Although Her2 amplification status was
not available for all of these samples, 60% (6 of 10) of the confirmed
TN lungmetastases contained Id1-expressing cancer cells (data not
shown). Interestingly, we also examined Id1 levels in 10 bone
metastases, but none of these samples contained tumor cells that
expressed Id1 (data not shown). These data are consistent with the
hypothesis that Id1 cells have a selectable advantage during
secondary metastasis to the lungs, especially in hormone receptor
negative breast cancers (see also Discussion).
Id1 and Id3 Expression in Transgenic Mouse Models of Breast Cancer.
To further investigate the biology of Id proteins among different
subtypes of breast cancer, we resorted to two distinct transgenic
mouse models of breast cancer—MTV-NeuYD and MMTV-
Wnt1. Mammary tumors induced by the Neu oncogene (16) have
a uniformly luminal histology (17), require CDK4 and cyclin D1
for transformation (18, 19), and are thought to reflect human
ErbB2 subtype breast cancer pathophysiology. In contrast,
Wnt1-driven tumors (20) are distinguished by a prevalence of
mammary progenitor-like cells (21–23), and exhibit many his-
topathological features in common with human basal subtype
tumors, including the presence of myoepithelial cells, dense
stromal and inflammatory infiltrates, and pushing margins of
invasion (17, 24). Additionally, a recent cross-species compari-
son of global gene expression patterns has characterized Wnt1-
driven mammary tumors as most similar to the basal subtype of
human breast cancer (25). Although designation of the basal
subtype is determined by microarray-based gene expression
profiles, immunohistochemical studies of basal breast cancers
have revealed that they all fall within the subgroup of TN tumors,
because they lack both ER and PR expression and Her2 gene
amplification (24).
Immunohistochemical staining for Id1 was performed on
mammary tumors arising in both the MMTV-Neu and MMTV-
Wnt1 mouse models. In addition, we also stained these mam-
mary tumors for Id3—the Id family member most closely related
to Id1, based on genetic studies documenting functional overlap
in mouse development and highly significant coexpression of Id1
and Id3 that is observed in large cohorts of human breast cancer
[supporting information (SI) Table 1]. Our results indicate that,
although both Neu and Wnt1 tumors exhibit Id expression in the
endothelial cells lining the tumor vasculature, only Wnt1-driven
tumors contain subsets of cancer cells that abundantly expressed
Id1 and Id3 (Fig. 2A). These immunohistochemical findings were
also confirmed by dissociation of Wnt and Neu tumors into
single cell suspensions, and by using FACS to separate endo-
thelial cells (CD31) from nonendothelial cells (CD31) in the
tumors, after initially depleting all cells expressing hematopoi-
etic lineage markers (by using the CD45 and Ter119 cell surface
markers). Quantitative RT-PCR analysis again validated that Id1
and Id3 expression was restricted to the endothelial compart-
ment of Neu tumors but was present in both endothelial and
nonendothelial cells in Wnt1 mammary tumors (Fig. 2B). The
enrichment of Id expression in Wnt1-induced mammary tumor
cells is reminiscent of our earlier observations of selective Id1
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Fig. 1. Expression of Id1 in human breast cancer tumors and lung metastases.
(A) Representative Id1 immunohistochemistry images of non-TN and TN pri-
mary breast tumors, acquired with an initial magnification of 20. (B) Id1
immunohistochemistry of a matched primary tumor and lung metastasis pair.
Nine of these pairs were analyzed, as discussed in the text. (Original magni-
fication: 20.) (C) Compiled results of Id1 immunohistochemistry performed
on 133 primary breast tumors. Frequencies of Id1 positivity in endothelial cells
and in cancer cells are shown. (D) Tabulated results of Id1 immunohistochem-
istry of 39 breast cancer lung metastases, with subset analysis based on
hormone receptor expression.P values were calculated by a two-tailed Fisher’s
exact test.
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expression in the TN subtype of human breast cancer and
supports the hypothesis that the expression of Id1 in breast
cancer is indeed nonuniform and may coincide with a more
undifferentiated/hormone-receptor-negative state.
Id1/Id3 Functional Requirement in Breast Tumor Initiation. To test the
functional importance of Id1 and Id3 in tumor initiation, we used
both MDA-MB-231 human breast cancer cells and primary cells
isolated fromWnt1- andNeu-drivenmousemammary tumors. The
MDA-MB-231 cell line is representative of the TN subset of breast
cancer and consists of cells with diverse metastatic potential that
can be sorted in vivo for specific metastatic tropisms (8, 26). The
lung metastasis gene expression signature (LMS) that includes Id1,
and predicts a high risk of lung metastatic recurrence in breast
cancer patients, was derived from this experimental system (8).
Expression analysis for all four Id family members revealed that Id1
and Id3 transcript levels in the in vivo-selected lung-metastatic
LM2–4175 subpopulation (8) were 8- and 4-fold higher, respec-
tively, than those in the unselected MDA-MB-231 parental popu-
lation, whereas Id2 and Id4 expression was similar in both
populations (SI Fig. 6). We confirmed this trend by immunohisto-
chemistry for Id1 in mammary tumors generated by parental
MDA-MB-231 cells and LM2–4175 cells (Fig. 3A). Knockdown of
Id1 and Id3 expression, both individually and in combination (Fig.
3B), resulted in partial and complete inhibition of mammary
tumor-initiating capacity, respectively (Fig. 3C). Similarly, com-
bined knockdown of mouse Id1/Id3 in MMTV-Wnt1 primary
tumor cells resulted in significant impairment of in vitro tumor
mammosphere generation as well as in vivo tumor initiation (Fig. 3
D and E), whereas the same knockdown construct introduced into
MMTV-Neu primary cells showed neither of these defects. Thus,
the selective expression of Id1 and Id3 in TN breast cancer cells
coincides with a functional requirement of Id expression for sus-
tained tumor-initiating capacity.
Id1/Id3 Functional Requirement for Lung Colonization.As previously
described, the in vivo-selected LM2–4175 subpopulation of the
parental MDA-MB-231 cell line exhibits aggressive lung meta-
static behavior when injected either intravenously or orthotopi-
cally into immunocompromised mice, and this capacity depends
on expression of genes included in the clinically validated LMS
(8). Immunohistochemistry demonstrates that these emergent
A 
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Fig. 2. Id1 and Id3 expression in transgenic mouse mammary tumor models.
(A) Representative Id1 and Id3 immunohistochemistry images of mammary
tumors from MMTV-Neu and MMTV-Wnt1 mice. (Original magnification:
20.) (B) Primary Neu and Wnt1 tumors were dissociated into single cell
suspensions and separated by FACS by using the CD31 and CD45 cell surface
markers. The CD31/CD45 fraction is enriched for endothelial cells, and the
CD31/CD45 fraction is composed mostly of tumor cells but may also contain
a minority of stromal cells. Total RNA was extracted from these samples, and
Id1 and Id3 mRNA levels normalized to GAPDH were measured by qRT-PCR.
Normalized expression values are shown relative to those obtained in the Neu
tumor CD31/CD45 fraction. Samples were analyzed in quadruplicate, and
error bars represent 95% confidence intervals. P values are based on a two-
tailed Student’s t test.
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Fig. 3. Functional requirement for Id1/Id3 in tumor-initiating capacity. (A)
Id1 immunohistochemistry of unselected MDA-MB-231 parental cells and
highly lung metastatic LM2 cells grown orthotopically in the mammary fat pad
of an immunocompromised mouse. (Original magnification: 20.) (B) qRT-
PCR analysis of Id1 and Id3 expression in LM2 cells retrovirally transduced with
short hairpin constructs targeting Id1, Id3, or both genes. Error bars indicate
95% confidence intervals of samples assayed in quadruplicate. (C) One thou-
sand control or ID knockdown LM2 cells were injected orthotopically into the
mammary glands of immunocompromised mice. Tumor volumes were as-
sessed at 9 weeks after inoculation. The P value is based on a two-tailed t test.
(D) Mammosphere-initiating capacity of primary Wnt1 and Neu tumor cells
transduced and sorted for shId1/Id3 or shLuc expression. Cells were incubated
in suspension at a concentration of 1,000 cells per ml, and mammospheres
were counted after 14 days of culture. Error bars represent the standard error
of the mean. The P value is based on a two-tailed t test. (E) Twenty-five
thousand primary Wnt and 100,000 primary Neu tumor cells expressing short
hairpins targeting luciferase or Id1/Id3 were injected into the mammary
glands of immunocompromised mice. Tumor volumes at 3 months are repre-
sented for all cohorts. The P value is based on a two-tailed t test comparison.
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lung metastases also express abundant levels of nuclear Id1 in a
subset of tumor cells comprising these lesions (Fig. 4A). To
determine whether this heterogeneous expression of Id proteins
is required for lung metastatic colonization, we injected control,
ID1 knockdown, ID3 knockdown, and combination knockdown
LM2–4175 cells intravenously, and monitored lung metastatic
outgrowth by using noninvasive bioluminescence imaging (8).
Analysis of these cohorts revealed statistically significant effects
of individual Id1 and Id3 knockdown on the extent of lung
metastatic outgrowth, with combination ID1/ID3 knockdown
resulting in complete suppression of lung metastatic coloniza-
tion (Fig. 4 B and C). Interestingly, the impairment in lung
metastasis was not due to a precipitous drop in signal within the
first week, but rather a decreased rate of cellular outgrowth
during the progression of organ colonization (Fig. 4B).
Id1/Id3 Mediate Sustained Tumor Cell Proliferation in the Lung Pa-
renchyma. To mechanistically characterize the functional defect
in Id1/Id3 knockdown LM2–4175 cells within the multistep
cascade of metastasis, we performed in situ analyses of lung
colonization within the first few weeks after i.v. inoculation.
Immunofluorescence staining for tumor cells and vascular en-
dothelium in lung tissue on day 5 after injection reveals numer-
ous LM2–4175 control cancer cells extravasating into the lung
parenchyma (Fig. 5ALeft), as has previously been described (10).
Similar analysis of lungs injected with the Id1/Id3 knockdown
cells showed no defect in in vivo extravasation, when compared
with the LM2–4175 control cells (Fig. 5A Right). This biological
activity was mimicked in vitro by using a transendothelial mono-
layer migration assay, which again demonstrated no deficiency in
the Id1/Id3 knockdown cells compared with LM2–4175 controls
(Fig. 5B), whereas parental MDA-MB-231 cells are markedly
impaired in this essential prometastatic function as are LM2 cells
with a quadruple knockdown of four lung metastasis genes,
namely EREG, MMP1, MMP2, and COX-2, that we have previ-
ously implicated in metastatic extravasation (10) (Fig. 5B). These
findings are in line with the observation that loss of Id1 and Id3
expression in these cells does not significantly alter the expres-
sion of these four metastatic extravasation genes (SI Fig. 7). Of
note, prior studies by others using a full-length antisense Id1
construct in breast cancer cells have reported a role for Id1 in
promoting invasiveness during metastatic progression (27, 28).
However, we are unable to document any role for Id1 or Id3 in
A 
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Fig. 4. Id1/Id3 are required for lung metastasis. (A) Id1 immunohistochem-
istry of lung metastases generated by injection of LM2 cells intravenously and
of lung metastases emerging from orthotopically implanted mammary fat
pad LM2 tumors. (Original magnification:20.) (B) Ten thousand control LM2,
Id single knockdown LM2, and combination Id1/Id3 knockdown LM2 cells
were injected intravenously, and lung metastatic outgrowth was monitored
by using bioluminescence imaging. The P value is based on a two-tailed
rank-sum test, compared with the control cohort. (C) Bioluminescence images
of representative mice from each cohort at day 0 and day 42.
Fig. 5. Id1/Id3 mediate sustained tumor proliferation during lung coloniza-
tion. (A) Reconstructed confocal images of 50-m-thick lung sections collected
3 days after i.v. inoculation of mice with LM2–4175 cells carrying a control
shRNA vector or LM2 cells with combination ID1/ID3 knockdown. Immuno-
fluorescence staining for CD31 (red) and tumor-specific vimentin (green) show
that tumor cells in both cases were able to successfully extravasate into the
lung parenchyma. (Original magnification:63.) (B) Quantification of in vitro
transendothelial migration of parental MDA-MB-231, control LM2 cells, ID1/
ID3 knockdown LM2, and EREG/COX2/MMP1/2 quadruple knockdown LM2
cells (4sh-RNAi). The P values are based on a two-tailed student’s t test. (C)
Coimmunofluorescence for Id1 (green), PCNA (red), and nuclei (DAPI, blue) in
an early stage lung metastasis generated by control LM2 cells. Blue arrow-
heads in the merged image indicate nuclei of cells that also stained positive for
tumor-specific vimentin (not shown). Yellow arrowheads indicate tumor cells
that show colocalization of Id1 and PCNA. (Original magnification: 63.)
Tabulation of 269 tumor cell nuclei that stain for PCNA and/or Id1 based on
analysis of multiple independent immunofluorescence images is also shown.
The P value was calculated by using a Fisher’s exact test for a 2 2 contingency
table. (D) Representative immunofluorescence images for tumor-specific vi-
mentin (red), the cell proliferation marker Ki-67 (green), and nuclear DAPI
(blue) in the lungs of mice that were intravenously inoculated with either
control or ID1/ID3 combination knockdown LM2 cells. Quantification of mul-
tiple lung sections at day 5 and day 10 demonstrates significant differences in
the rate of tumor cell proliferation. The P values are based on a two-tailed
Student’s t test. (E) A schematic representation of Id1/Id3 as mediators of
proliferative functions that enable efficient secondary tumor reinitiation
during lung metastasis.
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promoting invasion through extracellular matrix barriers by
using similar in vitro assays (SI Fig. 8). Collectively, our in vitro
and in vivo data point toward a role for Id proteins during
metastatic progression that is distinct from invasion through
either extracellular matrix or endothelial barriers.
Because Id proteins have been implicated as facilitators of
progenitor cell proliferation during organismal development (11),
we next considered a possible role for Id1 and Id3 as regulators of
disseminated cancer cell proliferation within the lung microenvi-
ronment. Toward this end, we costained relatively early stage lung
metastases from mice injected with LM2–4175 control cells (day
21) for Id1 and PCNA. Consistent with a role for Id1 in prolifer-
ation, quantitative analysis of multiple metastatic foci identified a
highly significant coincidence of Id1 and PCNA within tumor cell
nuclei (Fig. 5C). Interestingly, although the majority of Id1-
expressing cells were actively proliferating, there were also many
PCNA cells that lacked Id1 expression (Fig. 5C).
To determine if this level of Id1 and Id3 expression is
necessary for the early reinitiation of proliferation during lung
metastatic colonization, we costained lungs of mice 5 and 10 days
after injection with either control LM2–4175 or ID1/ID3 knock-
down LM2–4175 cells for the proliferative marker Ki-67 and a
tumor cell specific antigen. Staining of control cell-injected lungs
revealed multiple small foci of tumor cells that had efficiently
reentered the cell cycle (Fig. 5D, upper immunofluorescence
images). In contrast, lungs injected with ID1/ID3 knockdown
LM2–4175 cells predominantly contained solitary tumor cells
that infrequently expressed Ki-67 (Fig. 5D, lower immunofluo-
rescence images). Quantification of multiple lung sections re-
vealed statistically significant reductions in proliferating tumor
cells between ID1/ID3 knockdown and control LM2–4175 met-
astatic cells at both day 5 and day 10 after inoculation (Fig. 5D).
Extrapolation based on bioluminescence data suggests that the
proliferation-defective ID1/ID3 knockdown cells will never form
metastatic colonies (refer to Fig. 4B). Collectively, these data
argue that Id1 and Id3 are necessary for sustained proliferation
during the early stages of metastatic colonization, subsequent to
tumor cell extravasation into the lung parenchyma (Fig. 5E).
Discussion
Metastatic colonization entails distinct biological functions that
collectively enable disseminated cancer cells to thrive in a
secondary site (1, 2). Thus, the role of Id1 and Id3 as providers
of sustained proliferative competence during lung metastatic
colonization by breast cancer cells must occur in the context of
a full complement of distinct prometastatic functions. These
additional functions may be contributed in part by other mem-
bers of the functionally derived and clinically validated LMS
gene set to which Id1 belongs. Indeed, the enforced overexpres-
sion of Id1 alone is not sufficient to render parental MDA-MB-
231 cells efficiently metastatic to the lungs (8). In separate
studies we have identified four other genes in the LMS set that
are not regulated by Id proteins, and that cooperatively mediate
tumor cell extravasation into the lung parenchyma (10). Thus,
the proliferative capacity provided by Id genes is one in a set of
rate-limiting functions that collectively underlie the biology of
breast cancer metastasis to the lungs, which can be discerned
through themechanistic analysis of distinct genetic subsets of our
previously characterized LMS (29).
A number of studies have pointed to a role for the Id proteins
in the metastatic progression of breast cancer. Overexpression of
Id1 has been shown to enhance the invasiveness of breast cancer
cells in in vitro assays, and facilitates sustained proliferation of
transfected cells that are cultured in serum-starved conditions
(11). Conversely, inhibition of Id1 expression in breast cancer
cells has a significant impact on the ability of breast cancer cells
to metastasize to the lungs in xenograft models (8, 28). Although
it has been suggested that invasiveness through extracellular
matrix material in vitro is impaired in tumor cells expressing
full-length antisense Id1 (27, 28), we do not discern any such
defect when using short hairpin RNAi targeting Id1 expression
in aggressively lung metastatic MDA-MB-231 cells. Further-
more, our in situ analyses of extravasation and early proliferation
indicate that Id1 and Id3 are required in vivo for the sustained
proliferative activity of metastatic tumor cells during the reini-
tiation of secondary tumors in the lung. The present insights into
the biology of Id proteins drawmechanistic parallels between the
sustained proliferation of tissue progenitor cells in development
and the proliferative competency required for tumor reinitiation
during metastatic colonization.
The role for Id proteins that we describe here applies to breast
cancer cells that express Id. Although early studies using com-
mercially available polyclonal antibodies described broad over-
expression of Id1 protein in a majority of human primary breast
tumors, recent data from studies using a new highly specific
rabbit monoclonal antibody indicate that the expression of Id1 is
not nearly as widespread (14). Our current analysis of whole
tumor block sections has strengthened these initial findings, but
it has also revealed a reduced sensitivity in detecting focal Id1
expression when examining sample cores in the context of tissue
microarrays. Collectively, these studies have established that Id1
expression in cancer cells is rarely seen in tumors characterized
by hormone receptor expression or Her2 gene amplification, but
it is observed in 36% of primary breast cancers that are negative
for these biomarkers (i.e., TN), with the greatest prevalence
occurring within the subset of TN tumors that exhibit a meta-
plastic morphology (86%). Interestingly, all of the breast tumors
examined (regardless of subtype) exhibited Id1 positivity within
endothelial cells lining the tumor vasculature, consistent with a
role for this protein in tumor angiogenesis (11–13). This selective
pattern of Id1 expression was also observed in mouse mammary
tumors induced by the Neu versus Wnt1 oncogenes, with Wnt1-
driven tumors containing an abundance of tumor cells that
express Id1. Wnt1-driven mammary hyperplasias and tumors
have previously been shown to contain mammary progenitor-
like cells (21–23). It remains possible that Id1 expression in
human breast tumors may also coincide with an increased
frequency of intratumoral mammary stem-like cells. Consistent
with this notion, recent gene expression studies of human breast
tumors identified coexpression of Id family genes and stem-like
genes in a subset of breast tumor-initiating cells (30). However,
rigorous investigation of a potential causal link between Id
expression and progenitor-like properties in breast cancer
should be the subject of future studies.
We are providing a demonstration that Id1 protein is ex-
pressed in human breast cancer lung metastases. Consistent with
a causal role in lung colonization, we observe an increased
prevalence of Id1 positivity among lung metastases compared
with primary tumors. Because population-based studies show
that TN tumors represent 16% of all breast tumor cases (31),
the frequency of Id1 staining that we observed in our primary
tumor cohort predicts that 6% (36% of 16%) of all human
breast tumors will show focal Id1 staining. Given that 26% of the
lung metastasis lesions that we analyzed were Id1, this repre-
sents an enrichment of Id1 at the lung metastatic site relative to
the primary tumor. This noteworthy clinical correlation implies
that the proliferative functions mediated by Id genes may be a
limiting requirement in the development of lung metastases in
patients with hormone-receptor-negative breast cancer. We also
note that none of the ER breast cancers that developed lung
metastases exhibited Id1 protein expression, suggesting that
either reinitiation of proliferation at secondary sites is not a
rate-limiting step for ER breast cancer cells or that these cells
adopt alternative mechanisms for tumor reinitiation. Thus,
mechanisms of metastasis may be distinct for different subtypes
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of breast cancer, with apparent implications for the optimal
clinical management of advanced breast cancer.
Experimental Procedures
Cell Culture. The MDA-MB-231 cell line was obtained from the
American Tissue Culture Collection (ATCC), and the LM2–
4175 derivative was generated as previously described (8). Pri-
mary MMTV-Wnt and MMTV-Neu mammary tumor cells were
freshly isolated from mechanically and enzymatically digested
mouse tumors.
Animal Studies. All animal experiments were performed in com-
pliance with protocols approved by the Institutional Animal Care
and Use Committee of the Memorial Sloan–Kettering Cancer
Center (MSKCC). Transgenic mice expressingMMTV-Wnt-1 have
been described previously (20), as have mice expressing MMTV-
Neu-YD (16). Immunocompromised NOD-Scid mice were ob-
tained between 4 and 6 weeks of age from either the National
Cancer Institute or Charles River Laboratories.
Histological Analysis. Tissue sections of formalin-fixed and paraffin-
embedded human breast carcinomas and lung metastases were
obtained from the files of the Department of Pathology in com-
pliance with protocols approved by the MSKCC Institutional
ReviewBoard. One hundred thirty-three such human breast cancer
specimens were sectioned with 5-m thickness and stained for Id1
by using rabbit monoclonal anti-Id1 clone 195–14 according to a
previously published protocol (14). Staining of endothelial cells
provided an internal positive control for each case. Determination
of ER, PR, and HER2 status of breast carcinoma samples was as
previously described (14). In addition, immunoperoxidase staining
for Id1 was performed on 5-m-thick sections of lung metastases
of breast carcinoma from 39 patients. For 11 of these patients,
matched primary breast tumor tissue samples were also available
and were included in our primary tumor cohort. Transgenic and
xenograft tissues were extracted after euthanization of mice and
sequential perfusion with PBS and 4% paraformaldehyde.
Additional methods used in this paper are described in
SI Methods.
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